Serum squamous cell carcinoma antigen is a predictive factor of outcomes in patients with locally advanced unresectable esophageal squamous cell carcinoma treated by definitive chemoradiotherapy

Aim: Definitive chemoradiotherapy (dCRT) is the standard treatment for locally advanced unresectable esophageal squamous cell carcinoma (LU-ESCC). This study aimed to describe results of dCRT T4 ESCC and evaluate pretherapeutic predictive factors outcomes. Methods: A total 133 patients with who received were grouped into those achieved a complete response (CR) or had residual disease (RD). The clinicopathologic variables compared between groups overall survival (OS) was evaluated. factor RD assessed prognostic OS identified. Results: Among patients, 31 (23%) CR. CR group significantly better than (89.9 months vs. 10.7 months; hazard ratio = 0.096; 95% confidence interval: 0.05-0.19; P < 0.001). Multivariate analysis showed that supracarinal tumor (OR 3.21; 0.016), higher serum SCC-Ag level (> 1.6 ng/mL) 2.86; 0.018), metastatic node invasion 3.19; 0.048) independent predictors RD. increased antigen 1.61; 0.022) an predictor poor survival. Conclusions: underwent LU-ESCC, 23% CR, long-term outcome these favorable. Increased levels also found be failure.